Medical Journals

Cardiac-specific Overexpression of Diacylglycerol Kinase Zeta Attenuates Left Ventricular Remodeling and Improves Survival After Myocardial Infarction.

Authors:
  • Niizeki Takeshi
  • Takeishi Yasuchika
  • Arimoto Takanori
  • Takahashi Hiroki
  • Shishido Tetsuro
  • Koyama Yo
  • Goto Kaoru
  • Walsh Richard A
  • Kubota Isao

From: Department of Cardiology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, Japan 990-9585.

American journal of physiology. Heart and circulatory physiology

  • Publish Date: Feb 2007
  • ISSN: 0363-6135
  • Volume: 292
  • Issue: 2
  • Pages: H1105-12
  • Medium: Print
  • Language: English
  • Citation (JAMA): Niizeki Takeshi, Takeishi Yasuchika, Arimoto Takanori, et al. Cardiac-specific Overexpression of Diacylglycerol Kinase Zeta Attenuates Left Ventricular Remodeling and Improves Survival After Myocardial Infarction.. Am. J. Physiol. Heart Circ. Physiol. Feb 2007;292:H1105-12

Abstract

Left ventricular (LV) remodeling, including cardiomyocyte necrosis, scar formation, LV geometric changes, and cardiomyocyte hypertrophy, contributes to cardiac dysfunction and mortality after myocardial infarction (MI). Although precise cellular signaling mechanisms for LV remodeling are not fully elucidated, G(q) protein-coupled receptor signaling pathway, including diacylglycerol (DAG) and PKC, are involved in this process. DAG kinase (DGK) phosphorylates DAG and controls cellular DAG levels, thus acting as a negative regulator of PKC and subsequent cellular signaling. We previously reported that DGK inhibited angiotensin II and phenylephrine-induced activation of the DAG-PKC signaling and subsequent cardiac hypertrophy. The purpose of this study was to examine whether DGK modifies LV remodeling after MI. Left anterior descending coronary artery was ligated in transgenic mice with cardiac-specific overexpression of DGKzeta (DGKzeta-TG) and wild-type (WT) mice. LV chamber dilatation (4.12 +/- 0.10 vs. 4.53 +/- 0.32 mm, P < 0.01), reduction of LV systolic function (34.8 +/- 8.3% vs. 28.3 +/- 4.8%, P < 0.01), and increases in LV weight (95 +/- 3.6 vs. 111 +/- 4.1 mg, P < 0.05) and lung weight (160 +/- 15 vs. 221 +/- 25 mg, P < 0.05) at 4 wk after MI were attenuated in DGKzeta-TG mice compared with WT mice. In the noninfarct area, fibrosis fraction (0.51 +/- 0.04, P < 0.01) and upregulation of profibrotic genes, such as transforming growth factor-beta1 (P < 0.01), collagen type I (P < 0.05), and collagen type III (P < 0.01), were blocked in DGKzeta-TG mice. The survival rate at 4 wk after MI was higher in DGKzeta-TG mice than in WT mice (61% vs. 37%, P < 0.01). In conclusion, these results demonstrate the first evidence that DGKzeta suppresses LV structural remodeling and fibrosis and improves survival after MI. DGKzeta may be a potential novel therapeutic target to prevent LV remodeling after MI.

Mesh Headings (Keywords): Animals, Atrial Natriuretic Factor, Collagen, Diacylglycerol Kinase, Disease Models, Animal, Down-Regulation, Fibrosis, Heart Ventricles, Isoenzymes, Mice, Mice, Transgenic, Myocardial Infarction, Myocardium, Myosin Heavy Chains, Natriuretic Peptide, Brain, Protein Kinase C, Protein Transport, RNA, Messenger, Time Factors, Transforming Growth Factor beta1, Up-Regulation, Ventricular Function, Left, Ventricular Remodeling


Check for Full Text / PubMed Unique Identifier (PMID): 17071729


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.